NewAmsterdam Pharma shares are trading lower. The company announced its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.
Portfolio Pulse from Benzinga Newsdesk
NewAmsterdam Pharma shares are trading lower after the company announced its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.
July 29, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NewAmsterdam Pharma shares are trading lower following the announcement of its phase 3 BROOKLYN trial results for Obicetrapib in reducing LDL-C.
The announcement of the phase 3 BROOKLYN trial results for Obicetrapib has led to a decline in NewAmsterdam Pharma's share price. This suggests that the market may have had higher expectations for the trial outcomes, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100